Clinical trials: Vascular Patients
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH).
- Trial name
- ROCSTAR (NCT07175038)
- Testing
- ROC-101
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AllRock Bio, Inc.
Acute Stroke
Efficacy of EMF BCI Based Device on Acute Stroke
The study tests the efficacy of a non-invasive device with low intensity electromagnetic field dedicated treatment to enhance the recovery of stroke patients impaired hand motor function
- Trial name
- NCT04039178
- Testing
- BQ
- Where
- India
- Volunteers
- 28 people
- Sponsor
- BrainQ Technologies Ltd.
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT04398485
- Testing
- ION251
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertension
An Observational Study to Investigate the Efficacy, Safety, Tolerability and the Effect on Quality of Life of Telmisartan (Micardis) and Telmisartan With HCTZ (Micardis Plus) in Patients With Hypertension
An observational study to investigate the efficacy, safety, tolerability and the effect on quality of life of Telmisartan (Micardis) and Telmisartan with HCTZ (Micardis Plus) in patients with hypertension
- Trial name
- NCT00904215
- Testing
- telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)
- Where
- 11 sites in South Korea
- Volunteers
- 1,095 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Stenosis
DESolve® X-Pand Global Post Market Registry
The X-Pand Registry is intended to facilitate analysis of acute \& long-term safety as well as treatment outcomes with DESolve in patients with CAD.
- Trial name
- X-Pand (NCT02453035)
- Testing
- PTCA - Desolve Scaffold
- Where
- 5 sites in Germany, Netherlands
- Volunteers
- 154 people
- Sponsor
- Elixir Medical Corporation
Lymphedema
CVR Registry Evaluating Flexitouch Plus and Conservative Care vs Conservative Care Only for Treatment of Lymphedema
Subjects with lower extremity lymphedema will be prescribed, per standard of care, to either Flexitouch Plus with conservative care or conservative care only and be followed for 12 months.
- Trial name
- NCT04116099
- Testing
- Conservative care, Flexitouch Plus
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Tactile Medical
Hemorrhoids
Efficacy Study of Iferanserin to Treat Hemorrhoids
To evaluate the safety and efficacy of topical 0.5% S-MPEC cream vs. placebo cream (applied twice daily for 14 days) in the treatment of Grade I - III hemorrhoids.
- Trial name
- NCT01483833
- Testing
- Iferanserin
- Where
- Germany
- Volunteers
- 121 people
- Sponsor
- Ventrus Biosciences, Inc
Diabetic Foot Ulcer
Blue Light Photobiomodulation Therapy on Neuroischemic Patients
This is a pilot case/control clinical study on a group of outpatients with diabetic foot lesions aiming to verify the efficacy and safety of the Blue light photobiomodulation therapy with EmoLED medical device, in addition to…
- Trial name
- HERMES (NCT04831606)
- Testing
- debridement, Offloading, Advanced dressing
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- Emoled
Solid Tumors, Multiple Myeloma
Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma
The purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC. DCR-MYC is a novel synthetic double-stranded RNA in a stable lipid particle suspension that targets the oncogene…
- Conditions
- Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors
- Trial name
- NCT02110563
- Testing
- DCR-MYC
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Essential Hypertension
Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension
This study is to assess the safety and efficacy of an add-on treatment algorithm with olmesartan, hydrochlorothiazide and amlodipine in patients with mild to moderate hypertension.
- Trial name
- OLMETREAT (NCT00311155)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Where
- 79 sites in Austria, Belgium and 7 more
- Volunteers
- 694 people
- Sponsor
- Sankyo Pharma Gmbh
Macular Edema, Central Retinal Vein Occlusion
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
The purpose of the study is to evaluate the safety and tolerability of a single administration of FOV2302 (ecallantide) in patients with macular edema associated with central retinal vein occlusion.
- Trial name
- FOV2302 (NCT00969293)
- Testing
- FOV2302 (Ecallantide)
- Where
- 8 sites in France
- Volunteers
- 11 people
- Sponsor
- Fovea Pharmaceuticals SA
Multiple Myeloma
A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have…
- Trial name
- NCT02431208
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide
- Where
- 31 sites in United States
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Stroke, Stroke, Ischemic
MLC1501 Study Assessing Efficacy in STROke Recovery
This is a multi-center, randomized, double-blind, placebo-controlled, dose-response study of MLC1501 in patients with stroke. Eligible participants will be randomized in a 1:1:1 ratio to orally receive MLC1501 low-dose twice a…
- Conditions
- Stroke, Stroke, Ischemic, Strokes Thrombotic, Stroke Sequelae
- Trial name
- MAEStro (NCT05046106)
- Testing
- MLC1501
- Volunteers
- 540 people
- Sponsor
- Moleac Pte Ltd.
Hemiplegia, Hemiparesis
Evaluation of the Safety and Performance of the AWAKE Device in Patients With Hemiplegia or Hemiparesis Secondary to Stroke (ACV).
Stroke is a leading cause of disability in adults, with gait impairment being a key functional limitation. Although lower limb exoskeletons are used in rehabilitation, the available evidence focuses on bilateral devices used in…
- Trial name
- VAWAKE (NCT07867847)
- Testing
- Bionic System (AWAKE)
- Volunteers
- 20 people
- Sponsor
- Bionic Mobility Solutions, S.L.
Venous Thromboembolism
Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism
This study is a multicenter post authorization observational study. Cancer patients diagnosed with non high risk VTE and are followed up in an outpatient setting will be treated with LMWH and the data will be recorded.
- Trial name
- TREBECA (NCT02017743)
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Trio Grup Clinical Research
Hypotension
NOX-100 for Preventing Hypotension During Hemodialysis
This study is designed to evaluate the safety, tolerability and efficacy profile of NOX-100 to reduce intradialytic hypotension (IDH) in patients undergoing chronic hemodialysis (HD).
- Trial name
- NCT01672008
- Testing
- NOX-100
- Where
- 6 sites in Taiwan
- Volunteers
- 62 people
- Sponsor
- Medinox, Inc.
Multiple Myeloma
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.
- Trial name
- NCT01997840
- Testing
- ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- Celgene
Pulmonary Arterial Hypertension
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH).
- Trial name
- NCT00439946
- Testing
- treprostinil, Crono Five ambulatory pump
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- United Therapeutics
Hypertension
National Survey on Hypertension in General Practitioner (GP) Consultation
To evaluate (with sufficient accuracy) the profile(demographic and clinical characteristics, health care management) of hypertensive patients seen in general practitioner consultation.
- Trial name
- Prophyl GP (NCT00695656)
- Where
- 1,373 sites in France
- Volunteers
- 2,853 people
- Sponsor
- AstraZeneca
Coronary Heart Disease
A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient
Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel
- Trial name
- NCT01757262
- Testing
- 90 mg Ticagrelor, 75mg Clopidogrel
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.